These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 20237029)

  • 21. Radiation dose to the testes after 131I therapy for ablation of postsurgical thyroid remnants in patients with differentiated thyroid cancer.
    Ceccarelli C; Battisti P; Gasperi M; Fantuzzi E; Pacini F; Gualdrini G; Pierantoni MC; Luciani A; Djokich D; Pinchera A
    J Nucl Med; 1999 Oct; 40(10):1716-21. PubMed ID: 10520714
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Salivary and lacrimal gland dysfunction after remnant ablation with radioactive iodine in patients with differentiated thyroid carcinoma prepared with recombinant human thyrotropin.
    Rosario PW; Calsolari MR
    Thyroid; 2013 May; 23(5):617-9. PubMed ID: 23136908
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Randomized controlled trial of hydrochlorothiazide in augmenting the dose of 131I absorbed by thyroid remnant].
    Ding H; Kuang AR; Guan CT
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Jul; 35(4):546-8. PubMed ID: 15291124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pilocarpine effect on dose rate of salivary gland in differentiated thyroid carcinoma patients treated with radioiodine.
    Haghighatafshar M; Ghaedian M; Etemadi Z; Entezarmahdi SM; Ghaedian T
    Nucl Med Commun; 2018 May; 39(5):430-434. PubMed ID: 29517578
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radiation dose to family members of hyperthyroidism and thyroid cancer patients treated with 131I.
    Pant GS; Sharma SK; Bal CS; Kumar R; Rath GK
    Radiat Prot Dosimetry; 2006; 118(1):22-7. PubMed ID: 16105892
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity.
    Rosário PW; Borges MA; Purisch S
    J Nucl Med; 2008 Nov; 49(11):1776-82. PubMed ID: 18927337
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study.
    Taïeb D; Sebag F; Cherenko M; Baumstarck-Barrau K; Fortanier C; Farman-Ara B; De Micco C; Vaillant J; Thomas S; Conte-Devolx B; Loundou A; Auquier P; Henry JF; Mundler O
    Clin Endocrinol (Oxf); 2009 Jul; 71(1):115-23. PubMed ID: 18803678
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reducing the incidence of 131I-induced sialadenitis: the role of pilocarpine.
    Silberstein EB
    J Nucl Med; 2008 Apr; 49(4):546-9. PubMed ID: 18344428
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimized 124I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer.
    Jentzen W; Freudenberg L; Eising EG; Sonnenschein W; Knust J; Bockisch A
    J Nucl Med; 2008 Jun; 49(6):1017-23. PubMed ID: 18483099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy.
    Bohuslavizki KH; Brenner W; Klutmann S; Hübner RH; Lassmann S; Feyerabend B; Lüttges J; Tinnemeyer S; Clausen M; Henze E
    J Nucl Med; 1998 Jul; 39(7):1237-42. PubMed ID: 9669401
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
    Jarzab B; Handkiewicz-Junak D; Wloch J
    Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pre-therapeutic (124)I PET(/CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer.
    Jentzen W; Hobbs RF; Stahl A; Knust J; Sgouros G; Bockisch A
    Eur J Nucl Med Mol Imaging; 2010 May; 37(5):884-95. PubMed ID: 20069293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Salivary gland function 5 years after radioactive iodine ablation in patients with differentiated thyroid cancer: direct comparison of pre- and postablation scintigraphies and their relation to xerostomia symptoms.
    Jeong SY; Kim HW; Lee SW; Ahn BC; Lee J
    Thyroid; 2013 May; 23(5):609-16. PubMed ID: 23153322
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Salivary gland scintigraphy after radio-iodine therapy. Functional scintigraphy of the salivary gland after high dose radio-iodine therapy (author's transl)].
    Albrecht HH; Creutzig H
    Rofo; 1976 Dec; 125(6):546-51. PubMed ID: 137852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A prospective clinical trial to assess the efficacy of radioiodine ablation as an alternative to completion thyroidectomy in patients with differentiated thyroid cancer undergoing sub-total thyroidectomy.
    Bal CS; Kumar A; Chandra P; Dwivedi SN; Pant GS
    Acta Oncol; 2006; 45(8):1067-72. PubMed ID: 17118841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cytogenetic study of thyroid patients treated with external irradiation or radioiodine].
    Katz N; Esik O; Füzy M; Gundy S
    Orv Hetil; 1998 Jun; 139(25):1521-6. PubMed ID: 9676113
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sialoendoscopic treatment for radioiodine induced sialadenitis.
    Kim JW; Han GS; Lee SH; Lee DY; Kim YM
    Laryngoscope; 2007 Jan; 117(1):133-6. PubMed ID: 17202942
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Salivary gland damage after 131I therapy in patients with differentiated thyroid cancer. Preliminary report].
    Macioszek A; Baczyk M; Kopeć T; Sowiński J
    Endokrynol Pol; 2008; 59(5):403-10. PubMed ID: 18979451
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amifostine is a potent radioprotector of salivary glands in radioiodine therapy. Structural and ultrastructural findings.
    Kutta H; Kampen U; Sagowski C; Brenner W; Bohuslavizki KH; Paulsen F
    Strahlenther Onkol; 2005 Apr; 181(4):237-45. PubMed ID: 15827693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of vitamin E and supragingival scaling on salivary gland function in patients with differentiated thyroid cancer treated with 131I.
    Cheng Y; Tong H; Li X; Zhang X; Fang J; Yue R; Huang N; Tian J; Yu F; Gao Y
    Nucl Med Commun; 2022 Sep; 43(9):995-1003. PubMed ID: 35950355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.